ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Using BCR::ABL1 monitoring in CML as a case study, we show how our proposed strategy can (i) generate complete longitudinal data, (ii) accurately forecast biomarker trajectories at three- and six-month horizons, and (iii) enable clinically relevant scenarios such as extending follow-up intervals for low-risk patients without loss of predictive accuracy.